Mylan Launches First Generic Version of Xibrom Ophthalmic Solution

Mylan Inc. MYL today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bromfenac Ophthalmic Solution, 0.09%, based on a development and supply agreement with Coastal Pharmaceuticals. This product is the first generic version of ISTA's Xibrom® Ophthalmic Solution, 0.09%, a treatment for postoperative inflammation in patients who have undergone cataract extraction.